MRK vs SNY: fair value comparison
Merck & Co., Inc. and Sanofi · Updated 2026-10-19
SNY reports in EUR, so no same-currency fair-value verdict is published for it. Within Healthcare, MRK currently ranks higher by quality score.
| MRK | SNY | |
|---|---|---|
| Verdict | Overvalued | Awaiting full valuation |
| Last price | $145.60 | $40.67 |
| 12-month range | $82.49–$156.45 | $39.12–$52.34 |
| Rank by discount to fair value | #77 of 108 Healthcare | — |
| Rank by quality score | #120 of 301 Healthcare | #122 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Moderate | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | Modest | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Downtrend |
| DCF cross-check | Overvalued | — |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: MRK fair value analysis · SNY fair value analysis